In a report released today, James Fotheringham from BMO Capital maintained a Buy rating on Morgan Stanley (MS – Research Report), with a price target of $113.00. The company’s shares closed last Thursday at $84.76.
According to TipRanks.com, Fotheringham is a 5-star analyst with an average return of 17.0% and a 67.7% success rate. Fotheringham covers the Financial sector, focusing on stocks such as Discover Financial Services, International Money Express, and Victory Capital Holdings.
Morgan Stanley has an analyst consensus of Moderate Buy, with a price target consensus of $102.80, implying a 19.5% upside from current levels. In a report issued on April 14, Goldman Sachs also maintained a Buy rating on the stock with a $105.00 price target.
Based on Morgan Stanley’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $13.92 billion and net profit of $3.67 billion. In comparison, last year the company earned revenue of $14.81 billion and had a net profit of $4.12 billion.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1935, New York-based Morgan Stanley operates as a global financial services company and provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. The bank operates through three segments, including Institutional Securities, Wealth Management, and Investment Management.
Read More on MS:
- Raymond James Believes Chevron (CVX) Won’t Stop Here
- JB Hunt (JBHT) Receives a Buy from Raymond James
- Union Pacific (UNP) Receives a Rating Update from a Top Analyst
- Moody’s (MCO) Receives a Rating Update from a Top Analyst
- Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX) and Nektar Therapeutics (NKTR)